Please use this identifier to cite or link to this item:
|Title:||Anti-PSMA labeled liposomes loaded with Actinium-225 for potential antivascular alpha-radiotherapy|
|Authors:||ZHU Charles; BANDEKAR Amey; BANERJEE Sangeeta Ray; POMPER Martin; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; SOFOU Stavroula|
|Citation:||JOURNAL OF NUCLEAR MEDICINE vol. 55 no. Supplement 1 p. 640|
|Publisher:||SOC NUCLEAR MEDICINE INC|
|Type:||Articles in periodicals and books|
|Abstract:||We study targeted liposomes loaded with the alpha-particle generator Actinium-225 (225Ac) to selectively kill prostate-specific-membrane-antigen-(PSMA)-expressing cells with the aim to evaluate their potential for targeted antivascular alpha-radiotherapy. This bottom-up design contains the following: The targeted moiety is PSMA which is unique to human tumor vasculature for several different types of primary human cancers. The therapeutic radionuclide,225Ac, emits a total of four alpha-particles per decay providing highly lethal and localized irradiation of targeted cells with minimal exposure of surrounding healthy tissues. Finally, the delivery carrier is a lipid-based nanocarrier (a liposome). Liposomes can be loaded with high levels of radioactivity, and, in terms of toxicities, liposomes can be easily engineered to become rapidly cleared from circulation with the aim to shift the distribution of normal organ toxicities away from the kidneys (the dose limiting organ for 225Ac-labeled antibodies) and toward the spleen and/or liver.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.